BioCentury
ARTICLE | Financial News

Antiva raises $16M in series B

August 7, 2015 2:03 AM UTC

Antiva Biosciences Inc. (Menlo Park, Calif.) raised $16 million in a series B round co-led by new investors Canaan Partners and Sofinnova Ventures. Undisclosed existing investors also participated.

The proceeds will be used to advance lead compound ABI-1968 ( HTI-1968) through Phase I trials to treat human papillomavirus (HPV). The topical direct-acting antiviral is expected to enter Phase I trials in 2H16. ...